3 news items
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
ZLAB
20 May 24
of XACDURO® in the jurisdictions in which these products have been approved; the strategies, plans and objectives
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
CRDF
JNJ
NTBL
9 May 24
important new data sets supporting our first-line RAS-mutated mCRC strategy and the broader opportunity for onvansertib," said
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
ZLAB
27 Feb 24
This press release contains forward-looking statements relating to our strategy and plans; potential of and expectations for our business and pipeline
- Prev
- 1
- Next